Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2(Lp-PLA2): A review

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Silva, Isis T ^a   Mello, Ana P Q ^a   Damasceno, Nágila R T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antioxidant; Cardiovascular risk; Lp PLA2; pro inflammatory

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; REACTIVE OXYGEN METABOLITE; SELENIUM; SIMVASTATIN; TETRAHYDROLIPSTATIN; ANTIOXIDANT; AUTACOID; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHOLIPID;

ACUTE CORONARY SYNDROME; ANTIOXIDANT ACTIVITY; BIOCHEMISTRY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME STRUCTURE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID HYDROLYSIS; LIPID METABOLISM; LOW FAT DIET; MODULATION; NONHUMAN; NUTRITIONAL STATUS; OMNIVORE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; REVIEW; VEGETARIAN; ANIMAL; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MOLECULARLY TARGETED THERAPY; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; RISK FACTORS;

EID: 80053341923     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-170     Document Type: Review

References (84)

1. Demographics and cardiology, 1950-2050. Foot DK, Lewis RP, Pearson TA, Beller GA, J Am Coll Cardiol 2000 35 1067 1081 10.1016/S0735-1097(00)00561-1 10732909 (Pubitemid 30189942)
2. Global health risks: mortality and burden of disease attributable to selected major risks. World Health Organization, http://www.who.int/healthinfo/ global-burden-disease/GlobalHealthRisks-report-full.pdf Accessed January 10,2011
3. Lipoprotein-associated phospholipase a2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the prove it-timi 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Circulation 2006 113 1745 1752 10.1161/CIRCULATIONAHA.105.612630 16537575 (Pubitemid 43958467)
4. Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J, Arterioscler Thromb Vasc 2007 27 2463 2469 10.1161/ATVBAHA.107.151670 (Pubitemid 350203965)
5. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S, Eur Heart J 2009 30 107 15 19019993
6. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort. Li N, Li S, Yu C, Gu S, Postgrad Med 2010 122 200 205 10.3810/pgm.2010.07.2187 20675983
7. 2and C-Reactive protein for Measurement of Inflammatory Risk: Independent or Complementary? Iribarren C, Curr Cardio Risk Rep 2010 4 57 67 10.1007/s12170-009-0073-0
8. Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates plateletactivating factor (PAF). Farr RS, Cox CP, Wardlow ML, Jorgensen R, Clinical Immunology and Immunopathology 1980 15 318 30 10.1016/0090-1229(80)90044-6 7371225 (Pubitemid 10174770)
9. 2as a Cardiovascular Risk Marker. Corson MA, Jones PH, Davidson MH, Am J Cardiol 2008 101 suppl 41F 50F 18549871
10. Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis Biology, Epidemiology, and Possible Therapeutic Target. Zalewski A, Macphee C, Arterioscler Thromb Vasc Biol 2005 25 923 931 10.1161/01.ATV.0000160551.21962.a7 15731492 (Pubitemid 40627835)
11. Lp-PLA2-a novel risk factor for high-risk coronary and carotid artery disease. Epps KC, Wilensky RL, J InternMed 2011 269 94 106
12. Biology and biochemistry of platelet-activating factor. O'Flaherty JT, Wykle RL, Clin Rev Allergy 1983 1 353 367 6370406
13. PAF, aputative mediator of oral inflammation. Macmanus LM, Pinckard RN, Crit Rev Oral Biol Med 2000 11 2 240 258 10.1177/10454411000110020701 12002818 (Pubitemid 30481383)
14. Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF syntesis. Chen J, Yang L, Foulks JM, Weyrich AS, Zimmerman GA, Marathe GK, McIntyre TM, J Lipid Res 2007 48 11 2365 76 10.1194/jlr.M700325-JLR200 17693621 (Pubitemid 350058748)
15. Plasma PAF-acetylhydrolase: an unfulfilled promise? Karabina SA, Ninio E, Biochim Biophys Acta 2006 1761 1351 1358 16807087 (Pubitemid 44738700)
16. Platelet-activating factor: a phospholipid autacoids with diverse actions. Venable ME, Zimmerman GA, McIntyre TM, Prescott SM, J Lipid Res 1993 34 5 691 702 8389794 (Pubitemid 23152918)
17. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Snyder F, Biochim Biophys Acta 1995 1254 3 231 249 7857964
18. A specific acetylhydrolase for 1-alkyl-2- acetyl-sn-glycero-3- phosphocholine (a hypotensive and platelet-activating lipid). Blank ML, Lee T, Fitzgerald V, Snyder F, J Biol Chem 1981 256 175 178 7451433 (Pubitemid 12207103)
19. The growing phospholipase A2 superfamily of signal transduction enzymes. Dennis EA, Trends Biochem Sci 1997 22 1 2 10.1016/S0968-0004(96)20031-3 9020581 (Pubitemid 27056087)
20. Human Plasma Platelet-activating factor aceylhydrolase. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM, J Biol Chem 1991 266 17 11095 11103 2040620
21. Phospholipase A2 isoforms: a perspective. Chakraborti S, Cell Signal 2003 15 637 665 10.1016/S0898-6568(02)00144-4 12742226 (Pubitemid 36556070)
22. Purification and characterization of platelet-activating factor acetylhdrolase II from bovie liver cytosol. Hattori K, Hattori M, Adachi H, Tsujimoto, Arai H, Inoue K, J Biol Chem 1995 270 38 22308 22313 10.1074/jbc.270.38.22308 7673213
23. Platelet-activating factor acetylhydrolase. Arai H, Prostaglandins Other Lipid Mediat 2002 68-69 83 94 12432911 (Pubitemid 35247389)
24. PAF-acetylhydrolases. Derewenda ZS, Ho YS, Biochim Biophys Acta 1999 1441 229 236 10570251 (Pubitemid 29537743)
25. Platelet-activating factor and related lipidmediators. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM, Annu Rev Biochem 2000 69 419 45 10.1146/annurev.biochem.69.1.419 10966465
26. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M, Prostaglandins Leukot Essent Fatty Acids 2005 72 203 209 10.1016/j.plefa.2004. 10.021 15664305 (Pubitemid 40139085)
27. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase. Tselepis AD, Chapmam MJ, Atherosclerosis 2002 3 57 68 10.1016/S1567-5688(02)00045-4 12573364 (Pubitemid 38234487)
28. Characterization of a platelet activating factor acetylhydrolase from rat adipocyte. Chroni A, Mavri-Vavayanni M, Life Sci 2000 67 2807 2825 10.1016/S0024-3205(00)00870-5 11105997
29. Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase. Manya H, Aoki J, Kato H, Ishii J, Hino S, Arai H, Inoue K, J Biol Chem 1999 274 45 31827 32 10.1074/jbc.274.45. 31827 10542206 (Pubitemid 29522910)
30. Platelet activating factor acetylhydrolases. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM, J Biol Chem 1997 272 29 17895 8 10.1074/jbc.272.29. 17895 9218411 (Pubitemid 27306362)
31. Ratio of LDL- to HDL-Associated Platelet-Activating Factor Acetylhydrolase may be a Marker of Inflammation in Patients With Paroxysmal Atrial Fibrillation. Okamura K, Miura S, Zhang B, Uehara Y, Matsuo K, Kumagai K, Saku K, Circ J 2007 71 214 219 10.1253/circj.71.214 17251670 (Pubitemid 46182695)
32. Platelet-activating factor acetylhydrolases in health and disease. Tjoelker LW, Stafforini DM, Biochim Biophys Acta 2000 1488 102 123 11080681
33. Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II. Matsuzawa A, Hattori K, Aoki J, Arai H, Inoue K, J Biol Chem 1997 272 51 32315 20 10.1074/jbc.272.51.32315 9405438 (Pubitemid 28011912)
34. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. Han J, Hajjar DP, Febbraio M, Nicholson AC, J Biol Chem 1997 272 34 21654 9 10.1074/jbc.272.34. 21654 9261189 (Pubitemid 27374044)
35. Atherosclerosis: The Road Ahead. Glass CK, Witztum JL, Cell 2001 104 503 516 10.1016/S0092-8674(01)00238-0 11239408 (Pubitemid 32201946)
36. Electronegative low-density lipoprotein. Sánchez-Quesada JL, Benítez S, Ordá̃ez-Llanos J, Curr Opin Lipidol 2004 15 329 335 10.1097/00041433-200406000-00014 15166790 (Pubitemid 38716567)
37. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM, J Clin Invest 1995 96 5 2322 30 10.1172/JCI118288 7593619
38. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA, J Clin Invest 1995 95 2 774 82 10.1172/JCI117726 7860760
39. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Benítez S, Sánchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, González- Sastre F, Ordá̃ez-Llanos J, Circulation 2003 108 1 92 6 10.1161/01.CIR.0000072791.40232.8F 12821559 (Pubitemid 36859026)
40. Electronegative low-density lipoprotein: origin and impact on health and disease. Mello AP, da Silva IT, Abdalla DS, Damasceno NR, Atherosclerosis 2011 215 2 257 65 10.1016/j.atherosclerosis.2010.12.028 21292266
41. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Lourida ES, Papathanasiou AI, Goudevenos JA, Tselepis AD, Prostaglandins Leukot Essent Fatty Acids 2006 75 2 117 26 10.1016/j.plefa.2006.03.012 16843649 (Pubitemid 44287464)
42. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K, Arterioscler Thromb Vasc Biol 2003 23 5 829 35 10.1161/01.ATV.0000067701.09398.18 12649088 (Pubitemid 36566173)
43. Inflammation. A signal terminator. Bazan NG, Nature 1995 374 6522 501 2 10.1038/374501a0 7700374
44. Oxidized phospholipids as a new landmark in atherosclerosis. Itabe H, Prog Lipid Res 1998 37 2-3 181 207 10.1016/S0163-7827(98)00009-5 9829125 (Pubitemid 28391411)
45. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. Steinbrecher UP, Pritchard PH, J Lipid Res 1989 30 3 305 15 2723538 (Pubitemid 19082060)
46. Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. Frasch SC, Zemski-Berry K, Murphy RC, Borregaard N, Henson PM, Bratton DL, J Immunol 2007 178 10 6540 8 17475884 (Pubitemid 46717437)
47. Metabolism and atherogenic disease association of lysophosphatidylcholine. Schmitz G, Ruebsaamen K, Atherosclerosis 2010 208 1 10 8 10.1016/j.atherosclerosis.2009.05.029 19570538
48. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Quinn MT, Parthasarathy S, Steinberg D, Proc Natl Acad Sci USA 1988 85 2995 2998
49. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Lauber K, Bohn E, Kröber SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S, Cell 2003 113 6 717 30 10.1016/S0092-8674(03)00422-7 12809603 (Pubitemid 36724936)
50. Effects of lysophospholipids on the generation of reactive oxygen species by fMLP- and PMA-stimulated human neutrophils. Müller J, Petkovi M, Schiller J, Arnold K, Reichl S, Arnhold J, Luminescence 2002 17 3 141 9 10.1002/bio.681 12164363 (Pubitemid 135692504)
51. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A, Circulation 2007 115 21 2715 21 10.1161/CIRCULATIONAHA.106.671420 17502572 (Pubitemid 46842787)
52. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Herrmann J, Mannheim D, Wohlert C, Versari D, Meyer FB, McConnell JP, Gössl M, Lerman LO, Lerman A, Eur Heart J 2009 30 23 2930 8 10.1093/eurheartj/ehp309 19689974
53. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes. Kuniyasu A, Tokunaga M, Yamamoto T, Inoue S, Obama K, Kawahara K, Nakayama H, Biochim Biophys Acta 2011 1811 3 153 62 21146630
54. Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells. Vickers KC, Castro-Chavez F, Morrisett JD, Atherosclerosis 2010 211 1 122 9 10.1016/j.atherosclerosis.2010.04.005 20451909
55. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A, Clin Chem 2004 50 11 2077 82 10.1373/clinchem.2004. 036863 15364890 (Pubitemid 39425845)
56. Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Tsimihodimos V, Karabina SP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD, Arterioscler Thromb Vasc Biol 2002 22 306 311 10.1161/hq0202.102918 11834533 (Pubitemid 34127044)
57. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Eisaf M, Tselepis AD, Biochem Pharmacol 2003 66 11 2069 73 10.1016/S0006-2952(03)00559-8 14609731 (Pubitemid 37377852)
58. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, Landeloos M, Chapman MJ, Ninio E, Collen D, Himpens B, Holvoet P, FASEB J 2000 14 13 2032 9 10.1096/fj.99-1029com 11023987
59. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD, Nephrol Dial Transplant 2006 21 5 1270 7 10.1093/ndt/gfk043 16421163
60. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS, Lipids 2009 44 1 9 16 10.1007/s11745-008-3251-9 18956219
61. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. Noto H, Chitkara P, Raskin P, J Diabetes Complications 2006 20 6 343 8 10.1016/j.jdiacomp.2006.07.004 17070436 (Pubitemid 44633698)
62. The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH, J Vasc Surg 2007 46 3 500 6 10.1016/j.jvs.2007.04.038 17681710 (Pubitemid 47361606)
63. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S, Arterioscler Thromb Vasc Biol 2007 27 8 1788 95 10.1161/ATVBAHA.107. 145805 17541022 (Pubitemid 47207175)
64. The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort. Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G, Atherosclerosis 2007 190 388 396 10.1016/j.atherosclerosis.2006.02.016 16530769 (Pubitemid 46074030)
65. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD, Atherosclerosis 2010 209 2 528 32 10.1016/j.atherosclerosis.2009.09.021 19804884
66. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. The Lp-PLA2 Studies Collaboration, Lancet 2010 375 1536 44 20435228
67. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD, Atherosclerosis 2004 177 1 193 201 10.1016/j.atherosclerosis.2004.07.030 15488884 (Pubitemid 39361156)
68. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC, J Lipid Res 1997 38 11 2281 8 9392426 (Pubitemid 27495387)
69. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD, J Lipid Res 2003 44 927 934 10.1194/jlr.M200452-JLR200 12611907 (Pubitemid 37279653)
70. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ, Am J Cardiol 2005 95 9 1025 32 10.1016/j.amjcard.2005.01.023 15842965 (Pubitemid 40544302)
71. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Zhang B, Fan P, Shimoji E, Itabe H, Miura S, Uehara Y, Matsunaga A, Saku K, Atherosclerosis 2006 186 2 291 301 10.1016/j.atherosclerosis.2005.07. 029 16154574 (Pubitemid 43200899)
72. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Circulation 2006 113 14 1745 52 10.1161/CIRCULATIONAHA.105.612630 16537575 (Pubitemid 43958467)
73. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF, Arterioscler Thromb Vasc Biol 2008 28 6 1172 8 10.1161/ATVBAHA.107.160739 18356553
74. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A, Integrated Biomarker and Imaging Study-2 Investigators, Circulation 2008 118 11 1172 82 10.1161/CIRCULATIONAHA.108.771899 18765397
75. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, Darapladib Investigators, J Am Coll Cardiol 2008 51 17 1632 41 10.1016/j.jacc.2007.11.079 18436114 (Pubitemid 351635837)
76. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN, Atherosclerosis 2007 193 2 428 37 10.1016/j.atherosclerosis.2006.07.010 16911813 (Pubitemid 47058108)
77. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, Elisaf M, J Cardiovasc Pharmacol Ther 2006 11 4 256 61 10.1177/1074248406296108 17220472 (Pubitemid 44936239)
78. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Rizos EC, Spyrou A, Liberopoulos EN, Papavasiliou EC, Saougos V, Tselepis AD, Elisaf M, Open Cardiovasc Med J 2007 1 22 6 18949087
79. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Pedersen MW, Koenig W, Christensen JH, Schmidt EB, Eur J Nutr 2009 48 1 1 5 10.1007/s00394-008-0758-z 19030909
80. Studies on HDL associated enzymes under experimental hypercholesterolemia: possible modulation on selenium supplementation. Kaur HD, Bansal MP, Lipids Health Dis 2009 8 55 10.1186/1476-511X-8-55 20015371
81. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB, Am J Clin Nutr 2010 91 786 93 10.3945/ajcn.2009.28870 20107195
82. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN, Nutr Metab Cardiovasc Dis 2008 18 7 477 82 10.1016/j.numecd.2007.04.004 17928209
83. 2as an important biomarker of cardiovascular risk in obese adolescents. Silva IT, Timm AS, Damasceno NRT, Eur J Clin Nutr in evaluation
84. Taiwanese female vegetarians have lower lipoprotein-associated phospholipase A2 compared with omnivores. Chen CW, Lin CT, Lin YL, Lin TK, Lin CL, Yonsei Med J 2011 52 1 13 9 10.3349/ymj.2011.52.1.13 21155029